Sino Biopharmaceutical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBHMY research report →
About the company
Sino Biopharmaceutical Limited operates as a prominent research and development-centric pharmaceutical conglomerate in the People's Republic of China, functioning as an investment holding company. Its operations are organized into three primary divisions: Modernized Chinese and Chemical Medicines, Investment activities, and other varied business ventures. The firm maintains an extensive product range covering numerous therapeutic categories.
- CEO
- S. Y. Tse
- IPO
- 2017
- Employees
- 24,379
- HQ
- Wan Chai, HK
Price Chart
- Market Cap
- $11.27B
- P/E
- 31.46
- P/S
- 2.29
- P/B
- 2.40
- EV/EBITDA
- 11.26
- Div Yield
- 2.11%
- Gross Margin
- 82.07%
- Op Margin
- 21.84%
- Net Margin
- 7.36%
- ROE
- 7.22%
- ROIC
- 8.99%
- Revenue
- $30.97B · 7.28%
- Net Income
- $2.28B · -34.87%
- EPS
- $2.60 · -35.00%
- Op Income
- $6.63B
- FCF YoY
- 45.35%
- 52W High
- $20.16
- 52W Low
- $9.48
- 50D MA
- $13.31
- 200D MA
- $16.57
- Beta
- 0.60
- Avg Volume
- 16
Get TickerSpark's AI analysis on SBHMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SBHMY coverage
Recent articles, reports, and earnings notes.
No research on SBHMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBHMY report →Similar companies
Peers in the same neighborhood.